Terms ending in 2028
Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,964,726 | Tricyclic Compound and Use Thereof In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 8,008,449 | Human Monoclonal Antibodies to Programmed Death 1(PD-1) and Methods for Treating Cancer Using ANTI-PD-1 Antibodies Alone or in Combination with Other Immunotherapeutics In force · High confidence | E. R. Squibb & Sons, L.L.C. | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ono Pharmaceutical Co., Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.